Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

Biotechnology • Healthcare • Newton, MA, United States • ABOS (NMS)

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

617 344 4190 1210-1220 Washington St., Newton, MA 02465, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Yahoo Finance • Nov 28
B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq
Nasdaq • Nov 18
Acumen Pharmaceuticals (NASDAQ: ABOS) sets Nov. 12 webcast at 8 a.m. ET and call - Stock Titan
Stock Titan • Nov 5
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug - Investing.com
Investing.com • Nov 17
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - Yahoo Finance
Yahoo Finance • Aug 12

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Acumen Pharmaceuticals, Inc. had layoffs?
No layoff events have been recorded for Acumen Pharmaceuticals, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Acumen Pharmaceuticals, Inc. have?
Acumen Pharmaceuticals, Inc. has approximately 61 employees.
What industry is Acumen Pharmaceuticals, Inc. in?
Acumen Pharmaceuticals, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Acumen Pharmaceuticals, Inc. a publicly traded company?
Yes, Acumen Pharmaceuticals, Inc. is publicly traded under the ticker symbol ABOS on the NMS. The company has a market capitalization of approximately $0.13 billion.
Where is Acumen Pharmaceuticals, Inc. headquartered?
Acumen Pharmaceuticals, Inc. is headquartered in Newton, MA, United States at 1210-1220 Washington St., Newton, MA 02465, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.